A phase I/II study of the effect of intravenous anti-IL-5 (mepolizumab) SB 240563 on the outcome and management of hypereosinophilic syndromes.

Trial Profile

A phase I/II study of the effect of intravenous anti-IL-5 (mepolizumab) SB 240563 on the outcome and management of hypereosinophilic syndromes.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Eosinophilia; Eosinophilic oesophagitis
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 May 2011 Planned end date changed from 1 Apr 2010 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 24 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top